ISIS PHARMACEUTICAL (ISI BE) stock market data APIs
€68.5838
0(0%)
as of December 23, 2025
Try our APIs with
free plan!
ISIS PHARMACEUTICAL Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for ISI.BE.
Prev. Close
68.5838
Open
68.5838
High
68.5838
Low
68.5838
52 wk Range
22.5-70.66
Market Cap
3 685 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ISIS PHARMACEUTICAL data using free add-ons & libraries
Get ISIS PHARMACEUTICAL Fundamental Data
ISIS PHARMACEUTICAL Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ISIS PHARMACEUTICAL News
New
Has Ionis Pharmaceuticals Run Too Far After 135% Surge and Bullish DCF Outlook?
If you are wondering whether Ionis Pharmaceuticals is still a smart buy after its big run, or if most of the upside is already reflected in the price, you are not alone. That is exactly what we are go...
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerate...
Ionis receives U.S. FDA Breakthrough Therapy designation for zilganersen for Alexander disease (AxD)
– First and only investigational medicine for this rare, often fatal neurological condition – – On track to submit new drug application (NDA) in Q1 2026 – CARLSBAD, Calif., December 02, 2025...
Ionis Pharmaceuticals (IONS): Valuation Insights Following FDA Breakthrough Therapy Status for Olezarsen
Ionis Pharmaceuticals (IONS) caught investor attention after announcing its investigational drug olezarsen earned Breakthrough Therapy designation from the FDA for severe hypertriglyceridemia. The mov...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
